Sun Pharmaceutical Industries presented new data on LEQSELVI (deuruxolitinib) showing ongoing improvement in scalp hair regrowth for alopecia areata treatment at the 2024 Fall Clinical Dermatology Conference, with 68-week study results indicating a SALT response of 76.6%. The data suggest LEQSELVI is a preferred option among patients and clinicians for its efficacy and rapid onset of action.